On May 12th 2026, the Japan Patent Office notified TamaBio that it had granted a patent for the invention of “Artificial Blood Vessels and Methods for Manufacturing Artificial Blood Vessels.”
The development of artificial blood vessels is a responsibility and of great significance for medical device manufacturers.
Artificial blood vessels are devices that replace blood vessels that have ceased to function due to disease or injury, preventing the risk of rupture and saving lives in life-sustaining and disease treatment. TamaBio is working on the development of artificial blood vessels using ePTFE (expanded polytetrafluoroethylene). Tama Bio has successfully developed dura mater (approved in Japan, application pending in the US) and pericardium (approved in Japan and the US) using this material. Both have been implanted in the human body long-term (over 6,000 cases to date) with the intention of permanent implantation, and have demonstrated long-term stability, safety, and effectiveness, achieving expected treatment results without complications.
A major challenge with artificial blood vessels to date has been thrombosis in small-diameter blood vessels. When used in blood vessels with an inner diameter smaller than 4-6 mm, blood clots form and block the vessel, so they have not yet been put into practical use as a replacement for the small blood vessels used in cardiac bypass surgery. This patented technology acquired by TamaBio enables the development of antithrombotic artificial blood vessels.
Furthermore, the risk of infection was a challenge. Conventional artificial blood vessels have weak resistance to bacteria, and once an infection occurs, treatment tends to be prolonged. TamaBio’s permanent implantable artificial organ products, not limited to artificial blood vessels, have extremely high compatibility with biological tissue, suggesting that the occurrence of infection and inflammation can be prevented, which led to the acquisition of this patent.
In addition, artificial blood vessels carry the risk of tissue malformation (impaired healing). At the junction between the artificial blood vessel and the patient’s own biological blood vessels, cells do not properly integrate, making it difficult to completely integrate them into natural vascular tissue. This patent acquired by TamaBio directly addresses this very challenge.
TamaBio’s patented technology brings positive effects to vascular tissue and blood flow itself. Animal trials on blood vessels have also begun in Japan today. Tama Bio will continue to strive for the practical application of antithrombotic and highly biocompatible artificial blood vessels, in addition to developing the “NeuroBeam” device for treating cerebral infarction and brain nerve tissue damage, and the “CardioBeam” device for treating myocardial infarction.
For further details, please contact us using the inquiry form below or by contacting us directly.
Tetsuya Nagao／TamaBio Co.,Ltd. (MSE, Managing Director/CEO)
Registered (Tokyo) : A Class 1 Medical Devices Manufacturer & Distributor
PMDA Approval (DuraBeam® and PeriBeam®) : Class IV Highly Managed Medical Device
FDA Regulation Number : 870.3470, Classification Product Code DXZ
FDA Registration Number : 3041851334
Mobile +81 80 1196 3206 / Tel +81 422 53 5051 / FAX +81 422 38 5091
https://tamabio.com/en/
402 2-2-18 Sakai Musashino-shi Tokyo 180-0022 Japan